deferiprone has been researched along with Chronic Disease in 4 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions." | 8.83 | Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006) |
| "Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions." | 4.83 | Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006) |
| " The introduction of effective chelation therapy protocols using primarily deferiprone (L1) in combination with deferoxamine (DFO) resulted in the reduction of iron overload induced cardiac failures, which is the main cause of death in thalassemia major." | 3.75 | Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications. ( Kolnagou, A; Kontoghiorghes, GJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McLeod, C | 1 |
| Fleeman, N | 1 |
| Kirkham, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Chu, P | 1 |
| Dickson, R | 1 |
| Dundar, Y | 1 |
| Greenhalgh, J | 1 |
| Modell, B | 1 |
| Olujohungbe, A | 1 |
| Telfer, P | 1 |
| Walley, T | 1 |
| Kolnagou, A | 1 |
| Kontoghiorghes, GJ | 2 |
| Töndury, P | 1 |
| Zimmermann, A | 1 |
| Nielsen, P | 1 |
| Hirt, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients[NCT00349453] | Phase 2 | 24 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for deferiprone and Chronic Disease
| Article | Year |
|---|---|
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferipro | 2009 |
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Topics: Anemia; Chelation Therapy; Chronic Disease; Combined Modality Therapy; Deferiprone; Humans; Iron; Ir | 2006 |
2 other studies available for deferiprone and Chronic Disease
| Article | Year |
|---|---|
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
Topics: Chelation Therapy; Chronic Disease; Cyprus; Deferiprone; Deferoxamine; Female; Ferritins; Genetic Te | 2009 |
Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chronic Disease; Deferiprone; Ferritins; Hepatitis C; Humans; I | 1998 |